Extracorporeal Membrane Oxygenation Market Size By Modality (Venoarterial, Veno-venous, Arteriovenous), By Application (Cardiac, Respiratory, Extracorporeal cardiopulmonary resuscitation), By Patient Population (Infant, Paediatric, Adult), Industry Analys

Extracorporeal Membrane Oxygenation Market Size By Modality (Venoarterial, Veno-venous, Arteriovenous), By Application (Cardiac, Respiratory, Extracorporeal cardiopulmonary resuscitation), By Patient Population (Infant, Paediatric, Adult), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, Italy, France, Spain, China, India, Japan, Taiwan, Brazil, Mexico, Argentina, Saudi Arabia, UAE, South Africa,, Kuwait), Application Potential, Price Trends, Competitive Market Share & Forecast, 2018 - 2024

Extracorporeal Membrane Oxygenation Market will exceed USD 357 million by 2024; as per a new research report.

Increase in incidences of cardiopulmonary diseases and respiratory failure in developing regions will augment the extracorporeal membrane oxygenation market growth over the forecast years. Developed countries such as Japan should also witness increasing incidences of COPD dur to rapidly increasing. Total number of people seeking treatment for respiratory disease in Japan is around 260,000. The rising number of patient will propel the ECMO marker growth in upcoming years.

Rising patient awareness about benefits offered by extracorporeal membrane oxygenation device in Latin America region will result in tremendous industry growth. Increasing medical tourism, developing healthcare infrastructure and awareness among the people regarding application of ECMO in treatment of cardiopulmonary disorders will fuel the market growth.

High risks complications related to ECMO such as stroke, excessive bleeding, infection and pneumonia will be one of the major market impeding factor. According to a study conducted by National Institute for Health and Care Excellence, around 50% of the patients died during ECMO procedure due to severe bacterial infection and multiple organ failure. Aforementioned factors will play major role in restraining the industry growth.

Venoarterial (VA) ECMO market is estimated to grow with a CAGR of 4.3% during the projection years. Increasing use of Veno-arterial ECMO for resuscitating patients in cardiogenic shock will propel the segment growth. Venoarterial extracorporeal membrane oxygenation (ECMO) has to come up as perfect option to provide definitive and rapid mechanical circulation to the patients with cardiopulmonary failure or post cardiotomy patients with biventricular dysfunction.

Application of ECMO in cardiac diseases held significant market share with a total value of around USD 84.7 million 2017. According to European Heart Network, every year cardiovascular diseases account for around 4 million deaths in Europe. Increase in prevalence of cardiovascular diseases across the globe should drive the segment growth.

Infant patient population will experience lucrative growth from the year 2018 to 2024 at a robust CAGR of 3.0%. The neonatal respiratory patients have been treated most successfully with the help of ECMO. Increase in use of extracorporeal membrane oxygenation (ECMO) in infants suffering from severe cardiopulmonary failure will augment the segment growth in the near future.

U.S. extracorporeal membrane oxygenation market will witness significant growth in the forecast time frame at a CAGR of 2.6%. Enhanced healthcare infrastructure, presence of skilled labors and increasing prevalence of cardiovascular and respiratory diseases in the country will boost the regional market growth.

China extracorporeal membrane oxygenation market was valued over USD 13.7 million in the year 2017. According to the World Health Organization (WHO), China is facing an increasing epidemic of cardiovascular diseases with around 230 million people suffering from it. Rise in incidence of respiratory disorders among the people due to several environmental factors will fuel the regional industry growth in the upcoming years.

Some of the notable industry players are Getinge, Medtronic, Terumo, Abbott, LivaNova, and Alung Technologies, among others. Industry players are focusing on strengthening their research and development activities by launching technologically improved and enhanced ECMO devices along with initiating remote programs for customers to expand the market at rural level as well as sustain market position by adopting strategies such as partnership, strategic collaboration, acquisition and merger.


Chapter 1.Methodology
1.1. Methodology
1.1.1. Initial data exploration
1.1.2. Statistical model and forecast
1.1.3. Industry insights and validation
1.1.4. Market definition and forecast parameters
1.2. Data sources
1.2.1. Secondary
1.2.2. Primary
Chapter 2. Executive Summary
2.1. Extracorporeal Membrane Oxygenation industry 360 degree synopsis, 2013 - 2024
2.1.1. Business trends
2.1.2. Product trends
2.1.3. Application trends
2.1.4. Therapeutic trends
2.1.5. Regional trends
Chapter 3. Extracorporeal Membrane Oxygenation Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2013 - 2024
3.3. Industry impact forces
3.3.1. Growth drivers
3.3.1.1. Increase in cases of cardiopulmonary diseases and respiratory failure in Asia Pacific
3.3.1.2. Technological advancements in ECMO device in North America
3.3.1.3. Rising patient awareness about benefits delivered by extracorporeal membrane oxygenation device in Latin America
3.3.1.4. Rising government initiatives and programs in Europe
3.3.2. Industry pitfalls & challenges
3.3.2.1. High costs of equipment
3.3.2.2. Dearth of skilled professionals
3.3.2.3. Risks related to ECMO device
3.4. Growth potential analysis
3.4.1. By modality
3.4.2. By application
3.4.3. By patient population
3.5. Regulatory landscape
3.5.1. U.S
3.5.2. Europe
3.6. Porter's analysis
3.7. Competitive landscape, 2017
3.7.1. Business overview
3.7.2. Revenue analysis
3.7.3. Product landscape
3.7.4. Strategy dashboard
3.8. PESTEL analysis
Chapter 4. Extracorporeal Membrane Oxygenation Market, By Modality
4.1. Global Extracorporeal Membrane Oxygenation Market share, by modality, 2017 & 2024
4.2. Venoarterial (VA)
4.2.1. Market estimates and forecast, by region, 2013 - 2024
4.3. Veno-venous (VV)
4.3.1. Market estimates and forecast, by region, 2013 - 2024
4.4. Arteriovenous (AV)
4.4.1. Market estimates and forecast, by region, 2013 - 2024
Chapter 5. Extracorporeal Membrane Oxygenation Market, By Application
5.1. Global Extracorporeal Membrane Oxygenation Market share, by application, 2017 & 2024
5.2. Cardiac diseases
5.2.1. Market estimates and forecast, by region, 2013 - 2024
5.3. Respiratory diseases
5.3.1. Market estimates and forecast, by region, 2013 - 2024
5.4. Extracorporeal cardiopulmonary resuscitation (ECPR)
5.4.1. Market estimates and forecast, by region, 2013 - 2024
Chapter 6. Extracorporeal Membrane Oxygenation Market, By Patient Population
6.1. Global Extracorporeal Membrane Oxygenation Market share, by patient population, 2017 & 2024
6.2. Infant
6.2.1. Market estimates and forecast, by region, 2013 - 2024
6.3. Pediatric
6.3.1. Market estimates and forecast, by region, 2013 - 2024
6.4. Adult
6.4.1. Market estimates and forecast, by region, 2013 - 2024
Chapter 7. Extracorporeal Membrane Oxygenation Market, By Region
7.1. Extracorporeal Membrane Oxygenation Market share, by region, 2017 & 2024
7.2. North America
7.2.1. Market estimates and forecast, by country, 2013 - 2024
7.2.2. Market estimates and forecast, by modality, 2013 - 2024
7.2.3. Market estimates and forecast, by application, 2013 - 2024
7.2.4. Market estimates and forecast, by patient population, 2013 - 2024
7.2.5. U.S.
7.2.5.1. Market estimates and forecast, by modality, 2013 - 2024
7.2.5.2. Market estimates and forecast, by application, 2013 - 2024
7.2.5.3. Market estimates and forecast, by patient population, 2013 - 2024
7.2.6. Canada
7.2.6.1. Market estimates and forecast, by modality, 2013 - 2024
7.2.6.2. Market estimates and forecast, by application, 2013 - 2024
7.2.6.3. Market estimates and forecast, by patient population, 2013 - 2024
7.3. Europe
7.3.1. Market estimates and forecast, by country, 2013 - 2024
7.3.2. Market estimates and forecast, by modality, 2013 - 2024
7.3.3. Market estimates and forecast, by application, 2013 - 2024
7.3.4. Market estimates and forecast, by patient population, 2013 - 2024
7.3.5. Germany
7.3.5.1. Market estimates and forecast, by modality, 2013 - 2024
7.3.5.2. Market estimates and forecast, by application, 2013 - 2024
7.3.5.3. Market estimates and forecast, by patient population, 2013 - 2024
7.3.6. UK
7.3.6.1. Market estimates and forecast, by modality, 2013 - 2024
7.3.6.2. Market estimates and forecast, by application, 2013 - 2024
7.3.6.3. Market estimates and forecast, by patient population, 2013 - 2024
7.3.7. France
7.3.7.1. Market estimates and forecast, by modality, 2013 - 2024
7.3.7.2. Market estimates and forecast, by application, 2013 - 2024
7.3.7.3. Market estimates and forecast, by patient population, 2013 - 2024
7.3.8. Italy
7.3.8.1. Market estimates and forecast, by modality, 2013 - 2024
7.3.8.2. Market estimates and forecast, by application, 2013 - 2024
7.3.8.3. Market estimates and forecast, by patient population, 2013 - 2024
7.3.9. Spain
7.3.9.1. Market estimates and forecast, by modality, 2013 - 2024
7.3.9.2. Market estimates and forecast, by application, 2013 - 2024
7.3.9.3. Market estimates and forecast, by patient population, 2013 - 2024
7.4. Asia Pacific
7.4.1. Market estimates and forecast, by country, 2013 - 2024
7.4.2. Market estimates and forecast, by modality, 2013 - 2024
7.4.3. Market estimates and forecast, by application, 2013 - 2024
7.4.4. Market estimates and forecast, by patient population, 2013 - 2024
7.4.5. Japan
7.4.5.1. Market estimates and forecast, by modality, 2013 - 2024
7.4.5.2. Market estimates and forecast, by application, 2013 - 2024
7.4.5.3. Market estimates and forecast, by patient population, 2013 - 2024
7.4.6. China
7.4.6.1. Market estimates and forecast, by modality, 2013 - 2024
7.4.6.2. Market estimates and forecast, by application, 2013 - 2024
7.4.6.3. Market estimates and forecast, by patient population, 2013 - 2024
7.4.7. India
7.4.7.1. Market estimates and forecast, by modality, 2013 - 2024
7.4.7.2. Market estimates and forecast, by application, 2013 - 2024
7.4.7.3. Market estimates and forecast, by patient population, 2013 - 2024
7.4.8. Taiwan
7.4.8.1. Market estimates and forecast, by modality, 2013 - 2024
7.4.8.2. Market estimates and forecast, by application, 2013 - 2024
7.4.8.3. Market estimates and forecast, by patient population, 2013 - 2024
7.5. Latin America
7.5.1. Market estimates and forecast, by country, 2013 - 2024
7.5.2. Market estimates and forecast, by modality, 2013 - 2024
7.5.3. Market estimates and forecast, by application, 2013 - 2024
7.5.4. Market estimates and forecast, by patient population, 2013 - 2024
7.5.5. Brazil
7.5.5.1. Market estimates and forecast, by modality, 2013 - 2024
7.5.5.2. Market estimates and forecast, by application, 2013 - 2024
7.5.5.3. Market estimates and forecast, by patient population, 2013 - 2024
7.5.6. Mexico
7.5.6.1. Market estimates and forecast, by modality, 2013 - 2024
7.5.6.2. Market estimates and forecast, by application, 2013 - 2024
7.5.6.3. Market estimates and forecast, by patient population, 2013 - 2024
7.5.7. Argentina
7.5.7.1. Market estimates and forecast, by modality, 2013 - 2024
7.5.7.2. Market estimates and forecast, by application, 2013 - 2024
7.5.7.3. Market estimates and forecast, by patient population, 2013 - 2024
7.6. Middle East & Africa
7.6.1. Market estimates and forecast, by country, 2013 - 2024
7.6.2. Market estimates and forecast, by modality, 2013 - 2024
7.6.3. Market estimates and forecast, by application, 2013 - 2024
7.6.4. Market estimates and forecast, by patient population, 2013 - 2024
7.6.5. Saudi Arabia
7.6.5.1. Market estimates and forecast, by modality, 2013 - 2024
7.6.5.2. Market estimates and forecast, by application, 2013 - 2024
7.6.5.3. Market estimates and forecast, by patient population, 2013 - 2024
7.6.6. Qatar
7.6.6.1. Market estimates and forecast, by modality, 2013 - 2024
7.6.6.2. Market estimates and forecast, by application, 2013 - 2024
7.6.6.3. Market estimates and forecast, by patient population, 2013 - 2024
7.6.7. UAE
7.6.7.1. Market estimates and forecast, by modality, 2013 - 2024
7.6.7.2. Market estimates and forecast, by application, 2013 - 2024
7.6.7.3. Market estimates and forecast, by patient population, 2013 - 2024
7.6.8. South Africa
7.6.8.1. Market estimates and forecast, by modality, 2013 - 2024
7.6.8.2. Market estimates and forecast, by application, 2013 - 2024
7.6.8.3. Market estimates and forecast, by patient population, 2013 - 2024
Chapter 8. Company Profiles
8.1. Abbott Laboratories
8.1.1. Business overview
8.1.2. Financial data
8.1.3. Product landscape
8.1.4. Strategic outlook
8.1.5. SWOT analysis
8.2. Alung Technologies
8.2.1. Business overview
8.2.2. Financial data
8.2.3. Product landscape
8.2.4. Strategic outlook
8.2.5. SWOT analysis
8.3. Braile Biomedical
8.3.1. Business overview
8.3.2. Financial data
8.3.3. Product landscape
8.3.4. Strategic outlook
8.3.5. SWOT analysis
8.4. Edwards Lifesciences Corp
8.4.1. Business overview
8.4.2. Financial data
8.4.3. Product landscape
8.4.4. Strategic outlook
8.4.5. SWOT analysis
8.5. Elsius Biomedical Inc.
8.5.1. Business overview
8.5.2. Financial data
8.5.3. Product landscape
8.5.4. Strategic outlook
8.5.5. SWOT analysis
8.6. Eurosets Srl
8.6.1. Business overview
8.6.2. Financial data
8.6.3. Product landscape
8.6.4. Strategic outlook
8.6.5. SWOT analysis
8.7. Getinge Group
8.7.1. Business overview
8.7.2. Financial data
8.7.3. Product landscape
8.7.4. Strategic outlook
8.7.5. SWOT analysis
8.8. LivaNova PLC
8.8.1. Business overview
8.8.2. Financial data
8.8.3. Product landscape
8.8.4. Strategic outlook
8.8.5. SWOT analysis
8.9. Medtronic Inc.
8.9.1. Business overview
8.9.2. Financial data
8.9.3. Product landscape
8.9.4. Strategic outlook
8.9.5. SWOT analysis
8.10. MicroPort Scientific Corporation
8.10.1. Business overview
8.10.2. Financial data
8.10.3. Product landscape
8.10.4. Strategic outlook
8.10.5. SWOT analysis
8.11. Nipro Corporation
8.11.1. Business overview
8.11.2. Financial data
8.11.3. Product landscape
8.11.4. Strategic outlook
8.11.5. SWOT analysis
8.12. Origen Biomedical
8.12.1. Business overview
8.12.2. Financial data
8.12.3. Product landscape
8.12.4. Strategic outlook
8.12.5. SWOT analysis
8.13. Spectrum Medical
8.13.1. Business overview
8.13.2. Financial data
8.13.3. Product landscape
8.13.4. Strategic outlook
8.13.5. SWOT analysis
8.14. Terumo Corporation
8.14.1. Business overview
8.14.2. Financial data
8.14.3. Product landscape
8.14.4. Strategic outlook
8.14.5. SWOT analysis
Data Tables
TABAL 1. Extracorporeal membrane oxygenation industry 360 degree synopsis, 2013 - 2024
TABAL 2. Global extracorporeal membrane oxygenation market, 2013 - 2024 (USD Million)
TABAL 3. Global extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 4. Global extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 5. Global extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 6. Global extracorporeal membrane oxygenation market, by region, 2013 - 2024 (USD Million)
TABAL 7. Industry impact forces
TABAL 8. Venoarterial (VA) market, by region, 2013 - 2024, (USD Million)
TABAL 9. Veno-venous (VV)market, by region, 2013 - 2024, (USD Million)
TABAL 10. Arteriovenous (AV) market, by region, 2013 - 2024, (USD Million)
TABAL 11. Cardiac diseases market, by region, 2013 - 2024, (USD Million)
TABAL 12. Respiratory diseases market, by region, 2013 - 2024, (USD Million)
TABAL 13. Extracorporeal cardiopulmonary resuscitation (ECPR) market, by region, 2013 - 2024, (USD Million)
TABAL 14. Infant market, by region, 2013 - 2024, (USD Million)
TABAL 15. Pediatric market, by region, 2013 - 2024, (USD Million)
TABAL 16. Adult (VA) market, by region, 2013 - 2024, (USD Million)
TABAL 17. North America extracorporeal membrane oxygenation market, by country, 2013 - 2024 (USD Million)
TABAL 18. North America extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 19. North America extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 20. North America extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 21. U.S. extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 22. U.S. extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 23. U.S. extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 24. Canada extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 25. Canada extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 26. Canada extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 27. Europe extracorporeal membrane oxygenation market, by country, 2013 - 2024 (USD Million)
TABAL 28. Europe extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 29. Europe extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 30. Europe extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 31. Germany extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 32. Germany extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 33. Germany extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 34. UK extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 35. UK extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 36. UK extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 37. Italy extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 38. Italy extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 39. Italy extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 40. Spain extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 41. Spain extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 42. Spain extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 43. France extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 44. France extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 45. France extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 46. Asia Pacific extracorporeal membrane oxygenation market, by country, 2013 - 2024 (USD Million)
TABAL 47. Asia Pacific extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 48. Asia Pacific extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 49. Asia Pacific extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 50. China extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 51. China extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 52. China extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 53. India extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 54. India extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 55. India extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 56. Japan extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 57. Japan extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 58. Japan extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 59. Taiwan extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 60. Taiwan extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 61. Taiwan extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 62. Latin America extracorporeal membrane oxygenation market, by country 2013 - 2024 (USD Million)
TABAL 63. Latin America extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 64. Latin America extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 65. Latin America extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 66. Argentina extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 67. Argentina extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 68. Argentina extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 69. Brazil extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 70. Brazil extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 71. Brazil extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 72. Mexico extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 73. Mexico extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 74. Mexico extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 75. MEA extracorporeal membrane oxygenation market, by country 2013 - 2024 (USD Million)
TABAL 76. MEA extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 77. MEA extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 78. MEA extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 79. South Africa extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 80. South Africa extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 81. South Africa extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 82. UAE extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 83. UAE extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 84. UAE extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 85. Saudi Arabia extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 86. Saudi Arabia extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 87. Saudi Arabia extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
TABAL 88. Qatar extracorporeal membrane oxygenation market, by modality, 2013 - 2024 (USD Million)
TABAL 89. Qatar extracorporeal membrane oxygenation market, by application, 2013 - 2024 (USD Million)
TABAL 90. Qatar extracorporeal membrane oxygenation market, by patient population, 2013 - 2024 (USD Million)
Charts & Figures
FIG. 1 Industry segmentation
FIG. 2 Global extracorporeal membrane oxygenation market, 2013 - 2024 (USD Million)
FIG. 3 Industry ecosystem analysis
FIG. 4 Growth potential analysis
FIG. 5 Growth potential analysis
FIG. 6 Growth potential analysis
FIG. 7 Market share by prescriber's specialty
FIG. 8 Porter's Analysis
FIG. 9 Strategic Dashboard
FIG. 10 PESTEL Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook